drugset / Trial / NCT05014646
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Phase 2
Active not recruiting
27 enrolled
City of Hope Medical Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelPrevention
Summary
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
Timeline
- Start
- 2022-03-07
- Primary completion
- 2027-01-16
- Completion
- 2027-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leflunomide | Small molecule | — | Oral |
| Background | Cholestyramine | Other / unclassified | — | Oral |